股息配發率   玩股撇步(動畫小學堂)

  • 現金殖利率: 4.63%、總殖利率: 4.63%、5年平均現金配發率: 87.05%
  • 要留意資產負債表的未分配盈餘和配息能力, 如果為負值, 可能會無法發放股利
  • 股利有2個稅要支出, 分別是綜合所得稅和健保補充保費(單筆股利達2萬元以上, 課2.11%)
EPS YoY現金股利 YoY股票股利 YoY現金配發率 YoY股票配發率 YoY全部配發率 YoY
2023 (10)1.9417.581.6510.00.00085.05-6.440.00085.05-6.44
2022 (9)1.65-6.251.50-6.250.00090.910.00.00090.910.0
2021 (8)1.76-28.161.60-20.00.00090.9111.360.00090.9111.36
2020 (7)2.4511.872.005.260.00081.63-5.910.00081.63-5.91
2019 (6)2.19-3.951.902.70.00086.766.920.00086.766.92
2018 (5)2.28-4.61.852.780.00081.147.740.00081.14-17.48
2017 (4)2.39-2.851.8000.55075.31023.01098.330
2016 (3)2.46-1.20.0000.0000.0000.0000.000
每股盈餘-近20季
EPS QoQ YoY本業EPS QoQ YoY累計EPS QoQ YoY
23Q4 (20)0.7059.0942.860.5454.2928.571.9455.217.58
23Q3 (19)0.44-18.52-4.350.35-16.67-7.891.2554.327.76
23Q2 (18)0.54100.025.580.42121.0510.530.81200.015.71
23Q1 (17)0.27-44.90.00.19-54.76-29.630.27-83.640.0
22Q4 (16)0.496.52-5.770.4210.53-16.01.6542.24-6.25
22Q3 (15)0.466.98-16.360.380.0-24.01.1665.71-6.45
22Q2 (14)0.4359.262.380.3840.740.00.70159.261.45
22Q1 (13)0.27-48.08-3.570.27-46.00.00.27-84.66-3.57
21Q4 (12)0.52-5.45-34.180.500.0-35.061.7641.94-28.16
21Q3 (11)0.5530.953.770.5031.588.71.2479.71-25.3
21Q2 (10)0.4250.0-4.550.3840.74-9.520.69146.43-38.94
21Q1 (9)0.28-64.56-59.420.27-64.94-63.010.28-88.57-59.42
20Q4 (8)0.7949.06107.890.7767.3983.332.4547.5911.87
20Q3 (7)0.5320.4520.450.469.5221.051.6646.9-8.79
20Q2 (6)0.44-36.23-63.030.42-42.47-63.481.1363.77-18.71
20Q1 (5)0.6981.58331.250.7373.81284.210.69-68.49331.25
19Q4 (4)0.38-13.640.00.4210.530.02.1920.330.0
19Q3 (3)0.44-63.030.00.38-66.960.01.8230.940.0
19Q2 (2)1.19643.750.01.15505.260.01.39768.750.0
19Q1 (1)0.160.00.00.190.00.00.160.00.0
年/月營收月增率(%)去年同期年增率(%)累計營收累計營收年增率(%)近三月累計營收存貨銷售比自結稅前EPS自結稅前累計EPS備註(年增率變動50%需說明原因)
2024/30.1711.05-18.850.48-2.840.48N/A-
2024/20.15-4.98-26.380.318.770.66N/A-
2024/10.16-55.2199.20.1699.20.76N/A因去年1月適逢農曆春節工作天數較少,故營業額較去年同期增加所致。
2023/120.3545.1332.342.6512.210.820.31-
2023/110.2411.03-8.252.299.630.680.37-
2023/100.221.3938.032.0512.240.650.39-
2023/90.223.112.381.839.770.60.3-
2023/80.2123.6-3.721.619.430.750.24-
2023/70.17-53.43-8.341.411.720.760.24-
2023/60.3762.7561.081.2315.210.740.16本月儀器設備銷售額增加
2023/50.2250.6625.350.862.830.580.21-
2023/40.15-27.77-5.190.64-3.260.560.21-
2023/30.210.75-5.670.49-2.650.490.33-
2023/20.2157.1332.840.28-0.340.550.29-
2023/10.08-70.25-39.320.08-39.320.610.26-
2022/120.270.6146.832.363.660.690.22-
2022/110.2767.0314.252.09-0.10.620.24-
2022/100.16-17.44-6.351.82-1.90.570.26-
2022/90.19-11.67-5.541.67-1.450.60.23-
2022/80.2217.675.221.47-0.880.630.22-
2022/70.19-18.17-0.051.25-1.880.590.24-
2022/60.2326.6516.251.07-2.190.560.25-
2022/50.1813.9413.410.84-6.210.560.25-
2022/40.16-28.13-37.030.66-10.40.530.26-
2022/30.2241.94.40.53.190.50.24-
2022/20.1517.4423.960.292.280.470.26-
2022/10.13-28.0-15.140.13-15.140.550.22-
2021/120.18-21.7-41.692.28-23.850.590.19-
2021/110.2336.912.522.09-21.760.610.18-
2021/100.17-16.73-44.21.86-24.020.580.19-
2021/90.2-1.61-15.871.69-21.150.60.22-
2021/80.2111.77-1.471.49-21.820.590.22-
2021/70.19-4.8-6.41.28-24.360.540.24-
2021/60.223.5513.411.09-26.750.60.17-
2021/50.16-36.73-24.120.9-32.00.620.16-
2021/40.2519.1425.380.74-33.470.580.17-
2021/30.2168.47-46.150.49-46.340.490.31-
2021/20.12-19.6-67.690.28-46.490.590.25因去年同期儀器設備銷售額增加,導致本月較去年同期營收減少
2021/10.15-50.5213.190.1513.190.70.22-
2020/120.3137.6655.782.99-13.780.850.17因本月儀器設備銷售額增加,導致本月營收較去年同期增加
2020/110.23-25.49-2.542.68-18.060.780.18-
2020/100.3125.5556.082.45-19.260.760.18因取得客戶之儀器設備訂單於10月完成驗收,導致本月營收增加
2020/90.2415.2329.382.14-24.450.650.32-
2020/80.216.171.591.9-28.260.580.36-
2020/70.215.35-8.041.69-30.80.580.36-
2020/60.17-17.34-7.191.49-33.010.580.26-
2020/50.214.54-72.241.32-35.360.80.19因去年同期客戶新建醫療園區購置相關儀器設備陸續結案所致
2020/40.2-48.83-57.641.11-13.90.970.15因去年同期生技園區實驗動物相關儀器設備需求增加所致
2020/30.391.0890.070.9111.20.910.16因取得客戶之儀器設備訂單於3月完成驗收,導致本月營收增加
2020/20.39181.671.560.52-15.080.720.21-
2020/10.14-31.91-41.910.14-41.910.570.26-
2019/120.2-13.88-34.553.4718.030.630.43-
2019/110.2319.3232.183.2724.170.620.44-
2019/100.24.07-16.173.0323.60.590.46-
2019/90.19-9.51-73.012.8427.770.610.31107年因國家生技研究園區落成,實驗動物相關儀器設備陸續完成驗收,故去年同期認列儀器設備收入增加
2019/80.21-3.93.942.6573.790.610.31隨客戶新建園區購置相關儀器設備陸續結案所致
2019/70.2216.42-3.012.4484.311.150.16隨客戶新建園區購置相關儀器設備陸續結案所致
2019/60.19-75.27-13.392.23101.961.410.14隨客戶新建園區購置相關儀器設備陸續結案所致
2019/50.7559.53296.612.04129.790.0N/A隨客戶新建醫療園區購置相關儀器設備陸續結案所致
2019/40.47129.64173.521.2984.610.0N/A隨客戶生技園區實驗動物相關儀器設備需求增加所致

股利相關資訊

免責聲明

本網站所有資料僅供參考,如使用者依本資料交易發生交易損失需自行負責,本網站對資料內容錯誤﹑更新延誤不負任何責任。